Ethnie Jones, MD
Ophthalmology · Richmond, VANPI 1972611697
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $1,683,834 of the $1,971,403 with a category attached, or 85.4%. Medtronic accounts for 99.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $1,683,926 and has fallen 99.8% since, to $3,814 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $31,292 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2M
- Sun Pharmaceutical Industries Inc.$205
- AbbVie$183
- Alcon$166
- Rxsight Inc$150
- Aerie Pharmaceuticals, Inc.$96
- plus $283 from 11 others
What the payments were for
- Royalty or licence$1,683,83485%
- Speaking & faculty fees$30%
- Food & beverage$1,0800%
- Other$286,48615%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $1,970,320 |
| Sun Pharmaceutical Industries Inc. | 10 | $205 |
| AbbVie(2 entities) | 10 | $183 |
| Alcon | 6 | $166 |
| Rxsight Inc | 1 | $150 |
| Aerie Pharmaceuticals, Inc. | 5 | $96 |
| Tarsus Pharmaceuticals, Inc. | 2 | $49 |
| Novartis | 2 | $43 |
| Harrow Eye, LLC | 2 | $39 |
| Sight Sciences, Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| Thea Pharma Inc. | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Notal Vision, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,971,403 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 110 | $101,009 |
| LumiganBimatoprost | 86 | $35,011 |
| RocklatanNetarsudil Mesylat/Latanoprost | 47 | $28,970 |
| XiidraLifitegrast | 12 | $22,251 |
| Cyclosporine | 34 | $21,288 |
| Travoprost | 57 | $13,983 |
| Alphagan PBrimonidine Tartrate | 32 | $12,526 |
| Latanoprost | 970 | $10,862 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $9,428 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $8,296 |
| Brimonidine Tartrate | 127 | $5,277 |
| Prednisolone Acetate | 150 | $4,594 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 192 | $3,514 |
| Dorzolamide Hcl | 114 | $2,592 |
| ErythromycinErythromycin Base | 239 | $2,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $183 | $156,841249 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $96 | $28,97047 claims |
| AlconSimbrinza | $166 | $9,42826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Richmond
- Thomas JenkinsRichmond$26K
- Jessica RandolphRichmond$18K
- Nikisha RichardsRichmond$16K
- Tam DangRichmond$9K
- Byron LaddRichmond$7K
- Bryan SchwentRichmond$7K
- Rishi ParikhRichmond$6K
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.